Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Depreciation & Amortization (CF): 2023-2025

Historic Depreciation & Amortization (CF) for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $2.1 million.

  • Monte Rosa Therapeutics' Depreciation & Amortization (CF) fell 0.38% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 5.31%. This contributed to the annual value of $8.1 million for FY2024, which is 30.52% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Depreciation & Amortization (CF) of $2.1 million as of Q3 2025, which was down 1.41% from $2.1 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $2.1 million for Q2 2025, and its period low was $1.2 million during Q1 2023.
  • For the 3-year period, Monte Rosa Therapeutics' Depreciation & Amortization (CF) averaged around $1.9 million, with its median value being $2.0 million (2025).
  • As far as peak fluctuations go, Monte Rosa Therapeutics' Depreciation & Amortization (CF) spiked by 58.33% in 2024, and later dropped by 0.38% in 2025.
  • Monte Rosa Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $1.8 million in 2023, then increased by 11.65% to $2.1 million in 2024, then fell by 0.38% to $2.1 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $2.1 million for Q3 2025, versus $2.1 million for Q2 2025 and $2.0 million for Q1 2025.